Baseline demographic and clinical characteristics of the study population
| Characteristic | Group A (n = 28) | Group B (n = 29) | p value |
|---|---|---|---|
| FEV1, forced expiratory volume in 1 second; AQLQ, Asthma Quality of Life Questionnaire; ACQ, Asthma Control Questionnaire. | |||
| *Mean (95% CI). | |||
| †Median (IQR). | |||
| ‡Range (best–worst): 0–4; | |||
| ¶Range (best–worst): 0–6; | |||
| §Range (none–severe): 1–5 | |||
| **Atopic was defined as a positive skin prick test using the following criteria: length×width any allergen from a standard panel ⩾ length×width saline and ⩾ 3*3. | |||
| Sex (M : F) | 11 : 17 | 14 : 15 | 0.6768 |
| Smoking history (never : former) | 19 : 9 | 23 : 6 | 0.4960 |
| Atopy (non-atopic : atopic)** | 2 : 23 | 4 : 23 | 0.7383 |
| Oral corticosteroid use in past year (%) | 42.9 | 27.6 | 0.2143 |
| FEV1 (% predicted)* | 80.78 (74.52 to 87.03) | 78.93 (72.48 to 85.38) | 0.6760 |
| Reliever use (puffs/day)* | 2.94 (2.09 to 3.79) | 3.09 (2.22 to 3.95) | 0.8066 |
| AQLQ*‡ | 0.77 (0.57 to 0.96) | 0.54 (0.43 to 0.65) | 0.0417 |
| ACQ-7*¶ | 1.46 (1.22 to 1.70) | 1.37 (1.16 to 1.58) | 0.5653 |
| Daytime symptom intensity score†§ | 2.00 (1.00–3.00) | 2.00 (1.00–3.00) | 0.7251 |